Table 5 Factors associated with global treatment satisfaction

 Age (years)

< 50

Ref

–

–

Ref

–

–

Ref

–

–

50–64

1.15

0.91–1.45

0.236

0.99

0.77–1.26

0.917

1.03

0.81–1.32

0.795

65–74

0.87

0.69–1.09

0.222

0.71

0.56–0.91

0.007

0.75

0.59–0.96

0.025

≥ 75

0.87

0.66–1.13

0.284

0.55

0.41–0.73

< 0.001

0.64

0.48–0.86

0.003

 Sex

Female

1.24

1.02–1.52

0.034

1.00

0.81–1.24

0.999

1.13

0.91–1.40

0.277

 Disease duration (years)

≥ 11

1.28

1.09–1.49

0.002

1.06

0.89–1.25

0.508

1.13

0.93–1.38

0.225

 Pain VAS (cm)

> 1.2

4.33

3.65–5.14

< 0.001

2.16

1.74–2.67

< 0.001

–

–

–

 General VAS (cm)

> 0.9

3.02

2.56–3.55

< 0.001

1.18

0.96–1.45

0.115

–

–

–

 EQ5D score

0.9–1.0

Ref

–

–

Ref

–

–

–

–

–

0.85–0.89

2.51

1.85–3.39

< 0.001

2.14

1.56–2.92

< 0.001

–

–

–

0.75–0.84

3.46

2.78–4.30

< 0.001

2.79

2.21–3.52

< 0.001

–

–

–

0–0.74

8.60

6.90–10.71

< 0.001

5.93

4.60–7.65

< 0.001

–

–

–

 TJC

≥ 1

2.91

2.46–3.44

< 0.001

–

–

–

1.70

1.39–2.08

< 0.001

 SJC

≥ 1

2.48

2.09–2.93

< 0.001

–

–

–

1.24

1.01–1.51

0.040

 Log-transformed CRP (mg/dL)

Continuous

1.23

1.16–1.30

< 0.001

–

–

–

1.09

1.02–1.16

0.007

 Physician VAS (cm)

> 0.5

3.39

2.87–4.00

< 0.001

–

–

–

2.25

1.84–2.76

< 0.001

 Steinbrocker stage

3 and 4

1.56

1.33–1.83

< 0.001

–

–

–

1.15

0.93–1.42

0.198

 Musculoskeletal surgery

Yes

1.51

1.25–1.83

< 0.001

–

–

–

1.09

0.87–1.35

0.446

 Prednisolone dose (mg)

> 5

1.85

1.30–2.65

< 0.001

–

–

–

1.23

0.85–1.79

0.277

 Methotrexate use

Yes

0.84

0.70–0.99

0.0042

–

–

–

0.84

0.69–1.00

0.055

 b/tsDMARDs use

Yes

1.07

0.91–1.27

0.423

–

–

–

0.93

0.78–1.13

0.93